For example, dasatinib, which inhibits the nuclear localization of the YAP/TAZ complex, and verteporfin, which disrupts the formation of the YAP-TEAD complex, are currently used in clinical trials for chronic myeloid leukemia and metastatic breast cancer, respectively [29]. This evidence concerns the gene WWTR1 and chronic myelogenous leukemia, BCR-ABL1 positive.